Microinjection of Nonmuscle and Smooth Muscle Caldesmon into Fibroblasts and Muscle Cells

Yoshihiko Yamakita, Shigeko Yamashiro, and Fumio Matsumura

Department of Molecular Biology and Biochemistry, Nelson Laboratories, Rutgers University, Piscataway, New Jersey 08854-1059

Abstract. Caldesmon is present in a high molecular mass form in smooth muscle and predominantly in a low molecular mass form in nonmuscle cells. Their biochemical properties are very similar. To examine whether these two forms of caldesmon behave differently in cultured cells, we microinjected fluorescently labeled smooth muscle and nonmuscle caldesmons into fibroblasts. Simultaneous injection of both caldesmons into the same cells has revealed that both high and low relative molecular mass caldesmons are quickly (within 10 min) and stably (over 3 d) incorporated into the same structures of microfilaments including stress fibers and membrane ruffles, suggesting that nonmuscle cells do not distinguish nonmuscle caldesmon from smooth muscle caldesmon. The effect of calmodulin on the incorporation of caldesmon has been examined by coinjection of caldesmon with calmodulin. We have found that calmodulin retards the incorporation of caldesmon into stress fibers for a short period (10 min) but not for a longer incubation (30 min). The behavior of caldesmon in developing muscle cells was also examined because we previously observed that caldesmon disappears during myogenesis (Yamashiro, S., R. Ishikawa, and F. Matsumura. 1988. Protoplasma Suppl. 2: 9-21). We have found that, in contrast to its stable incorporation into stress fibers of fibroblasts, caldesmon is unable to be incorporated into thin filament structure (I-band) of differentiated muscle.

Caldesmon, first identified in smooth muscle, is a unique actin binding protein whose binding to actin is regulated by Ca²⁺/calmodulin (24). A wide variety of nonmuscle cells have been reported to contain caldesmon, which shows lower molecular masses on SDS gels than does smooth muscle caldesmon (ranging from 70,000 to 80,000 vs. 140,000 D of smooth muscle caldesmon) (3, 8, 16, 29). In cultured cells, nonmuscle caldesmons are found to be colocalized with actin, suggesting their involvement in microfilament organization and the regulation of cell motility. Both muscle and nonmuscle caldesmons have similar properties including a rodlike molecular shape, heat stability, calmodulin regulation of actin binding, self-association through disulfide bonds, periodic localization along actin filaments, and stimulation of actin binding of tropomyosin (1-3, 8, 16, 24, 28, 29). Bryan et al. have recently revealed a structural difference between these two types of chicken caldesmon through cDNA cloning (4; Bryan, J., R. Lee, S. J. Chang, and W. G. Lim. 1989. J. Cell Biol. 109[No. 4, Pt. 2]:189a [Abstr.]). While NH₂-terminal (200 amino acids) and COOH-terminal (324 amino acids) regions are exactly the same in smooth muscle and nonmuscle caldesmons, nonmuscle caldesmon is missing 232 amino acids from the central region of smooth muscle caldesmon, including a characteristic domain with an eightfold repeat of a 13 amino acid sequence. The sequence data together with the studies of domain mapping by others (11, 15, 22, 25, 30) have placed the actin- and calmodulin-binding domain at the COOH-terminal end of the molecule and the myosin binding domain at the NH₂ terminus. These studies have also revealed that caldesmons have much lower molecular masses than predicted by SDS-PAGE. The calculated molecular masses for chicken smooth muscle and nonmuscle caldesmons are 87,000 and 60,000 D, respectively.

The differences in biological functions of these caldesmons caused by the structural difference are not clear. The wide occurrence of the nonmuscle type of caldesmon in nonmuscle tissue and culture cells suggests that nonmuscle caldesmon may function in a way different from smooth muscle caldesmon. In this study, we have microinjected fluorescently labeled muscle and nonmuscle caldesmons into fibroblasts in order to see whether these two types of caldesmons behave differently in vivo. We have found that, unlike fibroblasts, muscle cells actively exclude caldesmon from thin filament structure.

Materials and Methods

Protein Purification

Smooth muscle caldesmon was purified from frozen bovine aorta and chicken gizzard by the method of Bretscher (1) with slight modification as
described (28). Nonmuscle caldesmon was purified from fresh bovine liver by the method described previously (28) except that the last hydroxyapatite column was omitted. COOH-terminal 40-kD fragments of chick gizzard smooth muscle caldesmon were prepared according to Fujii et al. (11). Skeletal muscle actin was purified as described previously (18). Alpha-actinin was purified from chicken gizzard as described by Feramisco and Burridge (9), and conjugated with FITC as described (23).

**Conjugation of Caldesmon with Fluorescent Dyes**

Caldesmons from smooth muscle and nonmuscle cells were conjugated with tetramethylrhodamine-5-(and-6)-iodoacetamide (TMRIA) or 5-iodoacetamidofluorescein (IAF) (Molecular Probes Inc., Eugene, OR). Caldesmons are known to form oligomers through disulfide bonds when reducing agents are removed by dialysis. Because this will eliminate free cysteine residues from caldesmon for conjugation with the dyes, we have conjugated caldesmons with excess amounts of the dyes over the concentration of reducing agents present in caldesmon preparation. In fact we found that caldesmon was conjugated very poorly with the dyes when reducing agents were removed by dialysis.

Caldesmons (1-5 mg/ml) in 20 mM Tris-acetate buffer containing 0.1 M KCI and 0.2 mM DTT were incubated with 0.5-1 mM of either TMRIA or IAF on ice for 4 h. The reaction was terminated by the addition of 2-mercaptoethanol to a final concentration of 50 mM. The free dye was removed by using Bio-Beads SM-2 (Bio-Rad Laboratories, Richmond, CA) as described (19). For purification of caldesmon with actin binding ability, dye-conjugated caldesmon (final concentration, 0.5 mg/ml) was incubated at room temperature for 1 h with 1 mg/ml of actin in 20 mM imidazole buffer of pH 7.0 containing 0.1 M KCI and 1 mM DTT. After centrifugation with an Airfuge (25 psi × 20 min; Beckman Instruments, Inc., Palo Alto, CA), the pellets were suspended in 50 μl of 20 mM potassium phosphate or 20 mM imidazole buffer of pH 7.0 containing 0.1 M KCI and 1 mM DTT. After heat treatment at 100°C for 10 min, dye-conjugated caldesmons (1 mg/ml) were recovered in the supernatants by centrifugation with an Airfuge, and used for microinjection or actin binding assay.

The dye/protein ratios of TMRIA-conjugated caldesmons were estimated based on a molar extinction coefficient of 47,000 at 552 nm (7), and assuming that molecular masses of nonmuscle and smooth muscle caldesmons were 60,000 and 87,000 D, respectively (4; Bryan, J., R. Lee, S. J. Chang, and W. G. Lim. 1989. J. Cell Biol. 109[No. 6, Pt. 2]:189a[Abstr.]).

**Cell Culture**

REF-52 cells (an established rat embryo cell line) and gerbil fibroblasts (CCL-146; American Type Culture Collection, Rockville, MD) were maintained in DME containing 10% newborn calf serum in an atmosphere of 5% CO₂ and 95% air at 37°C. Chick embryo myoblasts were prepared from the thigh muscle of an 11-d chick and cultured in DME supplemented with 15% horse serum and 2% of chick embryo extracts. They began to fuse at 2 d and differentiated into myotubes with sarcomere structures at ~10 d. Chick embryo fibroblasts were also maintained in DME supplemented with 15% horse serum and 2% of chick embryo extracts.

**Microinjection**

The technique of Graessmann and Graessmann (12) was used for microinjection of the fluorescently labeled proteins into cells. Needles were made with a Narishige needle puller and injection was performed with a Narishige micromanipulator (Narishige, Tokyo, Japan) attached to an Olympus in-

1. Abbreviations used in this paper: IAF, 5-iodoacetamidofluorescein; TMRIA, tetramethylrhodamine-5-(and-6)-iodoacetamide.

**Figure 1.** Actin binding of TMRIA-conjugated smooth muscle (A) and TMRIA-conjugated nonmuscle (B) caldesmons. Actin (0.5 mg/ml) was incubated for 1 h at room temperature with either 0.2 mg/ml of bovine aorta caldesmon (A) or 0.1 mg/ml of bovine liver caldesmon (B) in 20 mM imidazole buffer, 0.1 M KCI, and 0.5 mM DTT in the presence or absence of calmodulin (0.4 mg/ml). After centrifugation with an Airfuge (25 psi × 20 min), both supernatants and pellets are suspended in equal amounts of SDS sample buffer and analyzed by SDS-PAGE. Lane 1, molecular weight markers (from top to bottom, 200,000, 116,000, 97,000, 66,000, 43,000, 31,000, 21,000, and 14,000); lanes 2-7, actin binding of unconjugated caldesmon control; lanes 8-13 and a-f, actin binding of dye-conjugated caldesmons; lanes 1-13, Coomassie blue staining; lanes a-f, the same gel as in lanes 8-13 photographed with ultraviolet light. Lanes 3, 5, 7, 9, 11, 13, b, d, and f are pellets; lanes 2, 4, 6, 8, 10, 12, a, c, and e are supernatants. Lanes 2, 3, 8, 9, a, and b, are in the presence of calmodulin and 0.1 mM CaCl₂; lanes 4, 5, 10, 11, c and d, are in the presence of calmodulin and 1 mM EGTA; lanes 5, 6, 12, 13, e, and f, are in the absence of both calmodulin and CaCl₂.

**Results**

**Actin Binding Properties of Dye-conjugated Smooth Muscle and Nonmuscle Caldesmons**

For the conjugation of smooth muscle and nonmuscle caldesmons, we initially tested two kinds of fluorescent dyes that are different in the reactivities. One is iodoacetamides, which reacts with cysteine residues of protein. The other is isothiocyanates, which reacts with e-amino residues. Although caldesmons conjugated with either dye were observed to be incorporated into stress fibers when injected, caldesmon conjugated with the latter dyes showed much higher background and more diffuse staining than did caldesmon conjugated with the former dyes. We have thus chosen fluorescein or rhodamine iodoacetamide for this study. Dye-conjugated caldesmons were further purified by using
Figure 2. Binding of TMRIA-conjugated bovine liver caldesmon to cell models (REF-52 cells permeabilized with Triton X-100). (A) In the absence of calmodulin; (B) in the presence of Ca\(^{2+}\)/calmodulin.

We have examined actin binding properties of purified dye-conjugated bovine smooth muscle and nonmuscle caldesmons. As Fig. 1, A and B show, dye-conjugated caldesmons appear to show actin binding ability similar to that of intact proteins. Furthermore, actin binding of dye-conjugated smooth muscle and nonmuscle caldesmon is regulated by Ca\(^{2+}\)/calmodulin in the same way as that of intact molecule. Chick gizzard caldesmon labeled with the same dye also shows actin binding properties similar to those of intact proteins (data not shown).

To further examine the actin binding property of dye-conjugated caldesmons, we have examined their binding to a permeabilized cell model with or without calmodulin. When calmodulin is absent, TMRIA-conjugated liver caldesmons bind to stress fibers either in the presence or absence of Ca\(^{2+}\) (Fig. 2 A). When calmodulin is present, the binding is regulated by Ca\(^{2+}\)/calmodulin as is the binding of dye-conjugated caldesmons to actin (Fig. 1). In the presence of Ca\(^{2+}\), caldesmon shows very weak binding to stress fibers (Fig. 2 B), while caldesmon binds well to a cell model in the absence of Ca\(^{2+}\). Similar results were obtained with dye-conjugated smooth muscle caldesmon (data not shown).

Microinjection of Nonmuscle and Smooth Muscle Caldesmons into Fibroblasts

We then microinjected them into rat fibroblasts (REF 52 cells) to see their incorporation into the microfilament structures. As Fig. 3 shows, both bovine muscle and nonmuscle caldesmons are incorporated into stress fibers periodically (A and C). These patterns of the incorporation correspond to the localization of endogenous caldesmon revealed by immunofluorescence (Fig. 3 G).

The injected caldesmons, regardless whether they come from nonmuscle or smooth muscle cells, are quickly and stably incorporated into stress fiber structures. These caldesmons are observed in stress fibers within 10 min after injection and are stably present for over 3 d although the intensity of fluorescence is decreased by dilution due to cell division.

We have also examined incorporation of caldesmon into membrane ruffles because caldesmon is known to be localized in membrane ruffles as well. To this end, we have microinjected caldesmon into chick embryo fibroblasts, which have more membrane ruffle structures than REF 52 cells. As Fig. 3, E and F show, both bovine smooth muscle
and nonmuscle caldesmons are incorporated into membrane ruffles as well as stress fibers. Similar incorporation to microfilament structures is also seen with injection of dye-conjugated chick gizzard caldesmon (data not shown).

We have observed distribution of injected caldesmon in living cells because Cooper et al. (6) have shown that fixation changes the distribution of microinjected gelsolin from diffuse to fibrillar patterns. As Fig. 4 shows, injected caldesmon was observed to be incorporated into stress fibers of living REF 52 cells (Fig. 4 A), as well as membrane ruffles of living gerbil fibroma cells (Fig. 4 B). Although the background is somewhat higher than that of fixed images, the incorporation of caldesmon in living cells appears very similar to the pattern of distribution shown by fixed cells.

**Simultaneous Injection of Smooth and Nonmuscle Caldesmons into the Same Cells**

Because the incorporation of smooth muscle caldesmon appears to be similar to that of nonmuscle caldesmon, we asked whether these two types of caldesmons are incorporated into the same structures of microfilaments. To distinguish smooth and nonmuscle caldesmon in the same cells, these two caldesmons were separately labeled with two different dyes (TMRIA and IAF), mixed to make a equal molar concentration (6 μM of smooth muscle and 6 μM of nonmuscle caldesmon), and injected into REF 52 or gerbil fibroma cells. As Fig. 5, A, B, and C show, coinjected smooth muscle and nonmuscle caldesmons show indistinguishable incorporation into stress fibers in the same REF 52 cells. The injection into gerbil fibroma cells (Fig. 5, D, E, and F) has clearly demonstrated that two species of caldesmon are equally distributed into two different microfilament structures, i.e., stress fibers and membrane ruffles. The fluorescent structures derived from smooth muscle caldesmon are found to correspond exactly to those derived from nonmuscle caldesmon.

To examine whether these two species of caldesmon compete each other in the incorporation into stress fibers, we microinjected 5 μM (final concentration) of dye-conjugated bovine liver or chick smooth muscle caldesmon that had been mixed with varying concentrations (0–80 μM) of either smooth muscle or liver unconjugated caldesmon. If, for example, smooth muscle caldesmon bind to stress fibers better than nonmuscle species, smooth muscle unconjugated caldesmon would compete fluorescent nonmuscle caldesmon out of stress fibers more effectively than nonmuscle unconjugated caldesmon does. We have found, however, that both species of caldesmon give the same effects; fluorescently conjugated liver caldesmon on stress fibers was equally diluted out as the concentrations of unconjugated caldes-

![Figure 4. Distribution of TMRIA-conjugated caldesmon (1 mg/ml) in living REF-52 cells (A) and gerbil fibroma cells (B). The incorporation into stress fibers (A) and into membrane ruffles (B, arrows) is similar to those observed in fixed cells (Figs. 3 and 5).](image)
Figure 5. Simultaneous injection of smooth muscle and nonmuscle caldesmon into the same cells. REF-52 cells (A-C) or gerbil fibroma cells (D-F) were injected with a mixture of TMRIA-conjugated bovine aorta caldesmon (B and E) and IAF-conjugated bovine liver caldesmon (C and F). (A and D) Phase contrast; (B, C, E, and F) fluorescent image. Arrows show membrane ruffles. Note that two species of caldesmon are incorporated into the same structures of microfilaments. Injection with a mixture of IAF-conjugated smooth muscle and TMRIA-conjugated nonmuscle caldesmons gave similar results.
Figure 6. Smooth muscle and nonmuscle caldesmons do not compete each other in the incorporation into stress fibers. TMRIA-conjugated bovine liver caldesmon (final concentration, 5 μM) was first mixed with buffer alone (A), or varying concentrations of unconjugated smooth muscle (B, 40 μM; D, 80 μM) or nonmuscle (C, 40 μM; E, 80 μM) caldesmon, and injected into REF-52 cells. Fluorescent images were taken with a SIT video camera as described in Materials and Methods. Note that both species of caldesmon equally decrease the fluorescence of bovine liver caldesmon incorporated into stress fibers, suggesting that cells do not distinguish between these two species of caldesmon.
mon, regardless of species of caldesmon, were increased (Fig. 6). These results suggest that nonmuscle and smooth muscle caldesmons appear to have an indistinguishable ability of the incorporation into stress fibers.

Injection of COOH-Terminal Fragments into Fibroblasts

Because both high and low relative molecular mass caldesmons are incorporated into the same structures of stress fibers despite the structural differences, we asked whether even small fragments of caldesmon with the functional actin binding domain are incorporated into stress fibers. Studies on domain structure of gizzard caldesmon have revealed that the actin binding and calmodulin binding domain is localized in COOH-terminal 40-kD fragments (11, 15, 22, 25, 30). The protein sequence derived from cDNA cloning has revealed that one of the two cysteine residues of chick gizzard caldesmon are localized in the middle of the COOH-terminal fragments, allowing us to conjugate COOH-terminal fragments with TMRIA to see their incorporation. Dye-conjugated COOH-terminal fragments was also purified by co-sedimentation with F-actin and injected into REF-52 cells. As Fig. 7 shows, COOH-terminal fragments are incorporated into stress fibers. Their incorporation in some places appears periodic as seen in the case of the injection of intact molecule.

Effects of Coinjection with Calmodulin

Effects of coinjection of caldesmon with Ca\textsuperscript{2+}/calmodulin have been examined because actin binding of caldesmon is inhibited by Ca\textsuperscript{2+}/calmodulin in vitro. To ensure the complex formation, dye-conjugated caldesmon (1 mg/ml) is incubated with 20 times molar excess (final concentration, 4 mg/ml) of calmodulin over caldesmon in the presence of 0.1 mM of CaCl\textsubscript{2} and then injected into fibroblasts. As a control, caldesmon in 0.1 mM CaCl\textsubscript{2} but without calmodulin was injected. As Fig. 8, A and B show, coinjection with calmodulin retards the incorporation of caldesmon for a short time after injection. While control caldesmon without calmodulin (Fig. 8 B) is quickly incorporated into stress fibers within 10 min, most of caldesmon complexed with calmodulin (A) is diffusely present at the same time. The effect of calmodulin, however, disappears as the cells are incubated for longer than 30 min. As Fig. 8, C and D show, the incorporation of caldesmon coinjected with calmodulin (C) appears indistinguishable from that (D) of control.

Microinjection of Dye-conjugated Caldesmon into Muscle Cells

Our results indicate that caldesmon is a stable protein that remains bound to stress fibers over 3 d. On the other hand, we previously observed that nonmuscle caldesmon present in myoblasts disappears during fusion of myoblasts into myotubes (28). We have thus examined whether smooth muscle or nonmuscle caldesmon is stably incorporated into actin microfilaments of developing muscle cells. Chick myoblasts were used for this purpose because these cells are easily differentiated into myotubes with sarcomere structures.

As Fig. 9, A and B show, caldesmon is unexpectedly found in A-bands but not in I-bands when it is injected into myotubes with sarcomere structures. This A-band incorporation (Fig. 9 C) is quite unstable and quickly disappears after a 16-h incubation (Fig. 9 E). As a control, we have coinjected FITC-labeled α-actinin into myotubes. As Fig. 9, D and F show, α-actinin remains stably incorporated into Z-bands after 16 h. Similar results were obtained with the injection of smooth muscle caldesmon.

We have also injected caldesmon into myotubes that have...
not developed sarcomere structures. While caldesmon is found to be incorporated into microfilament bundles of myotubes, the incorporation is again very unstable and disappears after a 16-h incubation (data not shown). These results suggest that, unlike fibroblasts, muscle cells actively exclude caldesmon from their actomyosin system.

Discussion

Nonmuscle Cells Do Not Distinguish Smooth Muscle and Nonmuscle Caldesmons

Smooth muscle caldesmon has additional central regions (27 kD) including a repeated domain while both nonmuscle and smooth muscle share NH$_2$-terminal and COOH-terminal portions (4; Bryan, J., R. Lee, S. J. Chang, and W. G. Lim. 1989. J. Cell Biol. 109[No. 4, Pt. 2]:189a[Abstr.]). Our results indicate that the central domain does not inhibit the incorporation of caldesmon into actin structures of nonmuscle cells. Both smooth muscle and nonmuscle caldesmons are quickly and stably incorporated into stress fibers as well as membrane ruffles (Fig. 5). The incorporation is apparently normal because it is indistinguishable from the localization of endogenous caldesmon (Fig. 3). Furthermore, one species of caldesmon does not appear to compete the other out from stress fibers (Fig. 6). These results indicate that nonmuscle cells do not distinguish smooth muscle and nonmuscle caldesmons in terms of the incorporation into microfilaments. This notion is extended by the observation that a 40-kD actin and calmodulin binding proteolytic fragment is incorporated into stress fibers (Fig. 7), suggesting that caldesmon incorporation needs only the actin-binding domain.

The introduction of smooth muscle caldesmon at a concentration comparable to the endogenous nonmuscle caldesmon does not appear to affect the organization of the microfilament system in fibroblasts. The highest concentration of smooth muscle caldesmon used for microinjection was 7 mg/ml. Microinjection usually introduces ~$10^{-13}$ liter of solution into most fibroblasts (10), which allows for the introduction of $4 \times 10^6$ molecules per cell. Because ~$0.03-0.08\%$ of the cellular protein is nonmuscle caldesmon (Ishikawa, R., and F. Matsumura, unpublished results), each cell contains ~$2-6 \times 10^8$ molecules of caldesmon per

Figure 8. Effects of coinjection with calmodulin on the incorporation of caldesmon. A and C are fluorescent images at 10 and 30 min, respectively, after coinjection of TMR hA-conjugated caldesmon with calmodulin in the presence of 0.1 mM CaCl$_2$. B and D are fluorescent images at 10 and 30 min, respectively, after injection with TMR hA-conjugated caldesmon in 0.1 mM CaCl$_2$ without calmodulin.
cell assuming that a fibroblast contains ~1 ng of protein. The injected smooth muscle caldesmon thus roughly corresponds to the concentration of the endogenous caldesmon, but the injected caldesmon does not have any observable effects on the organization of microfilaments.

The incorporation of caldesmon into developing muscle cells is very different from its incorporation into fibroblasts. When caldesmon is injected into myotubes with sarcomere structures, it is unexpectedly incorporated into the A-band, rather than the I-band, just for a short time. On overnight incubation, caldesmon is excluded from muscle cells. This A-band incorporation is probably due to the direct binding of caldesmon to myosin (13, 14). These results are consistent with our previous observation that caldesmon disappears during fusion of myoblasts into myotubes but inconsistent with the report describing the presence of caldesmon in muscle cells (21). Further, these results suggest that thin filaments of developing muscle cells have some structure that inhibits the binding of caldesmon. At present, we do not know what inhibits the actin binding of caldesmon. One candidate for such structure may be tropinin/tropomyosin system. However, we could not observe competitive inhibition of actin binding of caldesmon by tropomyosin/troponin in vitro (data not shown).

Effects of the Modification of Cysteine Residues on the Actin Binding

The modification of thiol residues of chicken smooth muscle caldesmon or its 40-kD chymotryptic fragments with either fluorescein or rhodamin iodoacetamides does not appear to alter actin-binding properties of these proteins, nor to
change regulation of their actin binding by Ca$^{2+}$/calmodulin. This is consistent with the domain structure of the 40-kD fragments. According to the domain mapping studies (4, 22), a cysteine residue is located approximately at the middle of the 40-kD fragments, and COOH-terminal 25-kD fragments generated by chemical cleavage at the cysteine residue still retain actin and calmodulin binding properties.

Effects of Calmodulin

The coinjection of Ca$^{2+}$/calmodulin with caldesmon inhibits initial incorporation of caldesmon for 10 min. This retardation may represent the time period for the dissociation of a ternary complex of Ca$^{2+}$/calmodulin/caldesmon. The level of endogenous calmodulin in CHO cells is reported as 150 ng/10$^6$ cells (22). Assuming that REF 52 cells have the same level of calmodulin, the amount of calmodulin injected would be three to six times higher than the concentration of endogenous calmodulin, and this level of calmodulin would be high enough for the dissociation of both endogenous and exogenous caldesmon from actin filaments if calcium is present. This estimation may thus suggest that calcium concentration inside cells may be quickly dropped below the micromolar level. Other possibilities for this short-term effect by calmodulin are that calmodulin may be consumed for other cellular functions, or calmodulin may not function in the dissociation of caldesmon in vivo. Lehman, for example, questioned the regulatory role of calmodulin for the dissociation of caldesmon because he has observed that content of smooth muscle caldesmon is not changed when native thin filaments are prepared in either Ca$^{2+}$-free or Ca$^{2+}$-containing media in the presence of endogenous calmodulin (17). Further studies are needed for the elucidation of the biological significance of calmodulin regulation of actin-caldesmon interactions.

We thank Dr. F. Deis for critical reading of the manuscript. We also thank Ms. Purvi Tank for the help in initial microinjection experiments. This work was supported in part by grant R01 CA42742 from the National Cancer Institute, grant CD-442 from the American Cancer Society, Biomedical Research Support Grant PHS RR 07058-24, and Johnson and Johnson Discovery Fund. F. Matsumura is a recipient of Research Career Development Award K04 CA01304 from the National Cancer Institute.

Received for publication 5 March 1990 and in revised form 30 July 1990.

References

1. Bretscher, A. 1984. Smooth muscle caldesmon. J. Biol. Chem. 259:12873–12880.
2. Bretscher, A. 1986. Thin filament regulatory proteins of smooth and nonmuscle cells. Nature (Lond.) 321:726–727.
3. Bretscher, A., and W. Lynch. 1985. Identification and localization of immunoreactive forms of caldesmon in smooth and nonmuscle cells: a comparison with the distributions of tropomyosin and alpha-actinin. J. Cell Biol. 100:1656–1663.
4. Bryan, J., M. Imai, R. Lee, P. Moore, K. G. Cook, and W. Lim. 1989. Cloning and expression of a smooth muscle caldesmon. J. Biol. Chem. 264:13873–13879.
5. Deleted in proof.
6. Cooper, J. A., D. J. Lofhaus, C. Frieden, J. Bryan, and E. L. Elson. 1988. Localization and mobility of gelsolin in cells. J. Cell Biol. 106:1229–1240.
7. DeBiase, R. L., L.-L. Wang, G. W. Fisher, and D. L. Taylor. 1988. The dynamic distribution of fluorescent analogues of actin and myosin in protruions at the leading edge of migrating Swiss 373 fibroblasts. J. Cell Biol. 107:2631–2645.
8. Dingus, J., S. Hwo, and J. Bryan. 1986. Identification by monoclonal antibodies and characterization of human platelet caldesmon. J. Cell Biol. 102:1748–1757.
9. Feramisco, J. R., and K. Barridge. 1980. A rapid purification of α-actinin, filamin, and a 130,000-dalton protein from smooth muscle. J. Biol. Chem. 255:1194–1199.
10. Feramisco, J. R., M. Gross, T. Kamata, M. Rosenberg, and R. W. Sheet. 1984. Microinjection of the oncogenic form of the human H-ras protein results in rapid proliferation of quiescent cells. Cell. 38:109–117.
11. Fuji, T., M. Imai, G. Rosenfeld, and J. Bryan. 1987. Domain mapping of chicken gizzard caldesmon. J. Biol. Chem. 262:2757–2764.
12. Graessmann, H., and A. Graessmann. 1976. “Early” simian-virus-40-specific RNA contains information for tumor antigen formation and chromatin replication. Proc. Natl. Acad. Sci. USA. 73:366–370.
13. Hemric, M. E., and J. M. Chalovich. 1988. Effect of caldesmon on the ATPase activity and the binding of smooth and skeletal myosin subfragments to actin. J. Biol. Chem. 263:1878–1885.
14. Ikeda, M., and S. Reardon. 1988. Binding of caldesmon to smooth muscle myosin. J. Biol. Chem. 263:3055–3058.
15. Kobayashi, K., S. Yamada, K. Kanda, F. Kimizuka, J. Kato, and K. Sobue. 1989. 35-kDa fragment of b-caldesmon conserves two consensus sequences of the tropomyosin binding domain in troponin T. Biochem. Biophys. Res. Commun. 161:38–45.
16. Kojima-Owada, M., A. Hakura, K. Iida, I. Yahara, K. Sobue, and S. Kakiuchi. 1984. Occurrence of caldesmon (a calmodulin-binding protein) in cultured cells: comparison of normal and transformed cells. Proc. Natl. Acad. Sci. USA. 81:3133–3137.
17. Lehman, W. 1986. Caldesmon association with smooth muscle thin filaments isolated in the presence and absence of calcium. Biochem. Biophys. Acta. 885:88–90.
18. Matsumura, F., S. Yamashiro-Matsumura, and J. J.-C. Lin. 1983. Isolation and characterization of tropomyosin-containing microfilaments from cultured cells. J. Biol. Chem. 258:6636–6644.
19. McKenna, N. M., Y. Wang, and M. E. Kankel. 1989. Formation and movement of myosin-containing structures in living fibroblasts. J. Cell Biol. 109:1163–1172.
20. Means, A. R., J. S. Tash, and J. G. Chafoules. 1982. Physiological implications of the presence, distribution, and regulation of calmodulin in eukaryotic cells. Physiol. Rev. 62:1–39.
21. Naito, P. K., and M. W. Walsh. 1985. Detection of caldesmon in muscle and nonmuscle tissues of the chicken using polyclonal antibodies. Biochem. Biophys. Res. Commun. 127:533–539.
22. Riseman, E. P., W. P. Lynch, B. Nefsky, and A. Bretscher. 1989. The caldesmon and F-actin binding sites of smooth muscle caldesmon lie in the carboxyl-terminal domain whereas the molecular weight heterogeneity is in the middle of the molecule. J. Biol. Chem. 264:2869–2875.
23. Sanger, R., B. Mittal, and J. M. Sanger. 1984. Interaction of fluorescently labeled contractile proteins with the cytoskeleton in cell models. J. Cell Biol. 99:918–928.
24. Sobue, K., Y. Muramoto, M. Fujita, and S. Kakiuchi. 1981. Purification of a calmodulin-binding protein from chicken gizzard that interacts with F-actin. Proc. Natl. Acad. Sci. USA. 78:5652–5655.
25. Szpaczko, A., and R. Dabrowska. 1986. Functional domain of caldesmon. FEBS (Fed. Eur. Biochem. Soc.) Lett. 202:182–186.
26. Yamashiro-Matsumura, S., and F. Matsumura. 1985. Purification and characterization of an F-actin-binding 55 kilodalton protein from HeLa cells. J. Biol. Chem. 260:5087–5097.
27. Yamashiro-Matsumura, S., and F. Matsumura. 1986. Intracellular localization of the 55-kD actin-binding protein in cultured cells: spatial relationships with actin, alpha-actinin, tropomyosin, and fimbrin. J. Cell Biol. 103:631–640.
28. Yamashiro-Matsumura, S., R. Ishikawa, and F. Matsumura. 1988. Purification and characterization of an 83 kDa nonmuscle caldesmon from cultured rat cells: changes in its expression upon L6 myogenesis. Proteoliposomes Suppl. 2:9–21.
29. Yamashiro-Matsumura, S., and F. Matsumura. 1988. Characterization of 83-kD nonmuscle caldesmon from cultured rat cells: stimulation of actin binding of nonmuscle tropomyosin and periodic localization along microfilaments like tropomyosin. J. Cell Biol. 106:1973–1983.
30. Yawara, M., K. Yago, and K. Sobue. 1987. Isolation and characterization of a calmodulin binding fragment of chicken gizzard caldesmon. J. Biochem (Tokyo). 102:1065–1073.